Navidea Biopharmaceuticals, Inc. v. Capital Royalty Partners II, L.P.

2021 Ohio 808, 170 N.E.3d 472
CourtOhio Court of Appeals
DecidedMarch 16, 2021
Docket19AP-825
StatusPublished

This text of 2021 Ohio 808 (Navidea Biopharmaceuticals, Inc. v. Capital Royalty Partners II, L.P.) is published on Counsel Stack Legal Research, covering Ohio Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Navidea Biopharmaceuticals, Inc. v. Capital Royalty Partners II, L.P., 2021 Ohio 808, 170 N.E.3d 472 (Ohio Ct. App. 2021).

Opinion

[Cite as Navidea Biopharmaceuticals, Inc. v. Capital Royalty Partners II, L.P., 2021-Ohio-808.]

IN THE COURT OF APPEALS OF OHIO

TENTH APPELLATE DISTRICT

Navidea Biopharmaceuticals, Inc., :

Plaintiff-Appellee/ : Cross-Appellant, No. 19AP-825 : (C.P.C. No. 18CV-3097) v. : (REGULAR CALENDAR) Capital Royalty Partners II, L.P. et al., : Defendants-Appellants/ Cross-Appellees. :

D E C I S I O N

Rendered on March 16, 2021

On brief: Barnes & Thornburg LLP, Robert C. Folland, and David J. Dirisamer, for appellee/cross-appellant. Argued: Robert C. Folland.

On brief: Ulmer & Berne LLP, Andrew W. Owen and Rachael L. Rodman; Stinson L.L.P., Paul B. Lackey, and Michael P. Aigen, pro hac vice, for appellants/cross-appellees. Argued: Michael P. Aigen.

APPEAL from the Franklin County Court of Common Pleas

DORRIAN, P.J. {¶ 1} Defendants-appellants/cross-appellees Capital Royalty Partners II, L.P., Capital Royalty Partners II (Cayman), L.P., Capital Royalty Partners II – Parallel Fund "A," L.P., Parallel Investment Opportunities Partners II, L.P., Capital Royalty Partners II – Parallel Fund "B" (Cayman), L.P. and Capital Royalty Servicing, LLC ("Capital Royalty") appeal from a judgment of the Franklin County Court of Common Pleas which granted in part and denied in part the summary judgment motion of plaintiff-appellee/cross- appellant, Navidea Biopharmaceuticals, Inc. ("Navidea"), and granted in part and denied No. 19AP-825 2

in part Capital Royalty's motion for summary judgment. Navidea filed a cross-appeal from both the trial court's August 16, 2018 (motion to dismiss) and its November 27, 2019 (summary judgment motions) decisions. For the following reasons, affirm in part and reverse in part. I. Facts and Procedural History {¶ 2} Navidea is a biopharmaceutical company located in Dublin, Ohio, and Capital Royalty are lenders. In May 2015, Capital Royalty loaned Navidea an original principal amount of $50 million. As security for the loan, Navidea granted Capital Royalty first- priority liens and security interests in Navidea's property, including bank accounts and accounts receivable. Pursuant to the loan and security agreements, in the event of a default, Capital Royalty was granted certain rights, including the right to declare all outstanding obligations immediately due and payable, to take possession of all collateral without judicial process, and to direct Navidea's account receivables to be paid directly to Capital Royalty. {¶ 3} In 2016, disputes arose among the parties regarding the amount Navidea owed Capital Royalty, and alleged tortious actions by Capital Royalty against Navidea and the rightful ownership of funds held by Cardinal Health 414 LLC ("Cardinal"), who was Navidea's primary customer. These disputes led to litigation in both Ohio and Texas. {¶ 4} On April 7, 2016, Capital Royalty filed a lawsuit against Navidea in the Texas Harris County district court alleging Navidea was in default of its obligations under the loan agreement and sought a declaratory judgment that certain default events had occurred.1 Capital Royalty Partners II, L.P. v. Navidea Biopharmaceuticals, Inc., 151st District Court, Harris Cty. Texas No. 2016-22242 (Dec. 27, 2017) ("Capital Royalty, Texas No. 2016- 22242"). Capital Royalty requested that Cardinal forward all payments it owed to Navidea to Capital Royalty. {¶ 5} On June 16, 2016, Capital Royalty exercised its contractual right under the loan documents to require U.S. Bank to transfer funds amounting to $4,112,434.17 from a Navidea account to Capital Royalty. These funds are referred to as the "Swept funds."

1 Macrophage Therapeutics ("Macrophage"), a Delaware corporation, is listed as a defendant in the Texas

action, along with Navidea. Macrophage is a guarantor but not listed in Cardinal's interpleader complaint or Navidea's complaint filed in Ohio. No. 19AP-825 3

{¶ 6} Navidea filed counterclaims in the Texas action alleging: (1) aiding and abetting breach of fiduciary duty, (2) breach of contract, (3) breach of the duty of good faith and fair dealing, and (4) a declaratory judgment action seeking a declaration that Capital Royalty improperly applied approximately $4 million collected from Navidea to amounts not designated under the loan agreement. {¶ 7} On February 8, 2017, the Texas court granted partial summary judgment in favor of Capital Royalty holding that Navidea had committed one or more events of default under the loan documents and was liable for damages. Navidea filed a motion for reconsideration. The Texas trial court denied the motion. {¶ 8} On June 17, 2016, Cardinal filed an interpleader action in Ohio against Navidea and Capital Royalty to determine the true recipient of moneys to be paid by Cardinal under an agreement that Cardinal executed with Navidea and seeking an order directing Cardinal to pay the proper party. Cardinal Health 414, LLC v. Navidea Biopharmaceuticals, Inc., Franklin C.P. No. 16CV-5801 ("the first Ohio action"). On August 26, 2016, Navidea filed an answer and cross-claims against Capital Royalty in the interpleader action, alleging: (1) defamation, arguing that Capital Royalty falsely told Cardinal and others that Navidea had defaulted under the loan documents, (2) intentional interference with contract arguing that Capital Royalty interfered with the contract between Navidea and Cardinal, and (3) Navidea sought a permanent injunction to allow Navidea to use the funds Cardinal owed Navidea, including the funds at issue in the interpleader complaint and preventing Capital Royalty from taking possession of the funds. {¶ 9} On September 23, 2016 in the first Ohio action, Capital Royalty filed a motion to stay or, in the alternative, a motion to dismiss Navidea's cross-claims for injunctive relief and damages because of the pending Texas action. On November 21, 2016, the Ohio trial court granted leave for Navidea to file an amended cross-claim for injunctive relief and damages, which it filed on December 1, 2016, alleging defamation, interference with contract, abuse of process, and sought a permanent injunction preventing Capital Royalty from taking possession of the funds Cardinal owed Navidea. On January 24, 2017, the Ohio trial court denied Capital Royalty's motion to stay or, in the alternative, motion to dismiss. {¶ 10} Navidea, Capital Royalty, and Cardinal participated in negotiations with the Ohio trial court judge and reached an agreement, and the parties reduced their settlement No. 19AP-825 4

to writing in a document titled Global Settlement Agreement (the "Agreement"),2 signed March 3, 2017. As part of the Agreement: (1) Navidea, Capital Royalty, and Cardinal agreed to dismiss the claims in the first Ohio action with prejudice (section 1.5(a)), (2) dismiss the counterclaims in the Texas action with prejudice (section 2.1); however, Navidea retained the right to assert any claims and defenses to prove it only owed $47 million, not the $66 million as alleged by Capital Royalty (section 2.1), (3) Capital Royalty would release the liens on Navidea's property and each party would obtain a letter of credit to cover the final judgment (sections 1.4 and 2.1), and (4) Navidea agreed to pay Capital Royalty an amount to be determined by the Texas court but not less than $47 million and not more than $66 million with $59 million to be paid immediately after an asset sale to Cardinal by Navidea before March 10, 2017 (section 1.2). The Texas court was to determine the amount due pursuant to the underlying loan, any fees and other associated costs, and the Texas court would have exclusive jurisdiction over all matters regarding those issues and any issues regarding the letters of credit each party had to obtain.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Richardson v. Shaw
209 U.S. 365 (Supreme Court, 1908)
Durfee v. Duke
375 U.S. 106 (Supreme Court, 1963)
Fraser v. Doubleday & Co., Inc.
587 F. Supp. 1284 (S.D. New York, 1984)
Colavito v. New York Organ Donor Network, Inc.
860 N.E.2d 713 (New York Court of Appeals, 2006)
Nassar v. Florida Fleet Sales, Inc.
79 F. Supp. 2d 284 (S.D. New York, 1999)
Gilbert v. Summit County
2004 Ohio 7108 (Ohio Supreme Court, 2004)
Morgan v. Ohio State Univ. College of Dentistry
2014 Ohio 1846 (Ohio Court of Appeals, 2014)
Boston v. Sealmaster Industries, Unpublished Decision (8-13-2004)
2004 Ohio 4278 (Ohio Court of Appeals, 2004)
Carnegie Financial Corp. v. Akron National Bank & Trust Co.
361 N.E.2d 504 (Ohio Court of Appeals, 1976)
Pilz v. Dept. of Rehab. Corr., Unpublished Decision (8-3-2004)
2004 Ohio 4040 (Ohio Court of Appeals, 2004)
Dice v. White Family Companies, Inc.
878 N.E.2d 1105 (Ohio Court of Appeals, 2007)
Clark-Fitzpatrick, Inc. v. Long Island Rail Road
516 N.E.2d 190 (New York Court of Appeals, 1987)
Sommer v. Federal Signal Corp.
79 N.Y.2d 540 (New York Court of Appeals, 1992)
New York University v. Continental Insurance
662 N.E.2d 763 (New York Court of Appeals, 1995)
Tourtellot v. Architects Engineers & Construction Managers
55 A.D.3d 1096 (Appellate Division of the Supreme Court of New York, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
2021 Ohio 808, 170 N.E.3d 472, Counsel Stack Legal Research, https://law.counselstack.com/opinion/navidea-biopharmaceuticals-inc-v-capital-royalty-partners-ii-lp-ohioctapp-2021.